***Sponsored by Shore Thing Media, LLC
EUDA is a health technology company that operates a first-of-its-kind Southeast Asian digital healthcare ecosystem
EUDA Partners with Authorized Distributor of Guangdong Cell Biotech to Offer Stem Cell Therapies to Customers in Singapore and Malaysia
***JUST ANNOUNCED: EUDA Expands Wellness Product Portfolio With A Next-Generation Immune Health Supplement
_________________________
Hello Everyone,
Last week was busy and the market blessed us with a few double digit movers. The market is incredibly hot right now. We have AI, Tarrifs, Wars, Semiconductors, Crypto, Rate Cuts etc. etc. I could go on and on. There are so many factors and so many opportunities. We are definitely looking at all of these factors play out on a global stage right now.
Asia is the biggest market in the world. They are 60% of the worlds population. Singapore and Malaysia are two huge countries. Their combined GDP is just shy of 1 Trillion. This next company operates in these markets and just started to make some news announcements so we want to keep an eye on EUDA as we head into the opening bell.
EUDA just had a strong 3 day run before a nice double digit pull back today. I couldn’t be more excited to see what this one does come 9:30 am tomorrow.
EUDA is a leading non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia, and China. The Company aims to become a market leader in non-invasive and preventive healthcare, with a strategic focus on the fast-growing longevity sector. EUDA is looking to address the evolving healthcare needs of over 1.8 billion people across the region which is experiencing significant demographic shifts as more than 30% of the population ages rapidly. By offering innovative, accessible, and science-backed health solutions, EUDA is positioned to lead the transformation of regional healthcare from reactive medical treatment to proactive, longevity-focused care. EUDA also runs a Singapore-based property management business.
EUDA Health is pursuing a strategic expansion plan, bolstered by key acquisitions such as CK Health. This acquisition strengthens EUDA’s wellness portfolio and boosts its footprint across Malaysia, Vietnam, and Indonesia. CK Health brings exclusive distribution rights for products like bioenergy cabins and wellness supplements, including collagen drinks, which complement EUDA’s core medical services. These additions support EUDA’s commitment to delivering comprehensive healthcare solutions, enabling it to reach a wider audience. The company leverages multiple sales channels—direct sales, e-commerce, and retail networks—to tap into new revenue opportunities and sharpen its competitive edge in the fast-evolving healthcare and wellness sectors.
Southeast Asia’s healthcare industry is on track to hit $740 billion by 2025, driven by an aging population and growing healthcare needs. Positioned to benefit from this growth, EUDA offers an integrated suite of services, including urgent care, telemedicine, and wellness solutions. Its scalable model meets the rising demand for affordable, quality healthcare fueled by the expanding middle class in the region. By focusing on preventive care and chronic disease management, EUDA is well-placed to respond to the shifting needs of the Southeast Asian healthcare landscape.
Central to EUDA’s approach is a tech-enabled healthcare platform that utilizes artificial intelligence, machine learning, and data analytics. This allows for more personalized and efficient care, streamlining coordination across services such as emergency care, virtual doctor visits, and wellness support. AI-powered features like predictive analytics and smart triage help deliver faster, more accurate diagnoses, enhancing patient outcomes and minimizing operational inefficiencies. As a result, EUDA is emerging as a leader in Southeast Asia’s digital healthcare transformation.
EUDA’s telehealth and virtual clinic services offer patients 24/7 access to medical care, addressing the growing demand for convenient and cost-effective healthcare. Patients can consult with licensed physicians, receive prescriptions, and manage personalized care plans—all from home. This model proves especially valuable in rural and underserved regions, helping reduce healthcare access barriers. Further expanding its accessibility, EUDA is bringing its services into residential and commercial buildings through on-site clinics and telehealth kiosks. This move reinforces the company’s mission to make high-quality healthcare more accessible and affordable.
With its blend of urgent medical care and wellness offerings, EUDA is set to significantly expand its presence in Southeast Asia. The CK Health acquisition not only diversifies its service lineup but also enhances its holistic care model through products like bioenergy cabins and Yoroyal’s collagen supplements. Together, these components position EUDA as a leading healthcare provider in a region where healthcare expenditure is rapidly increasing and demand for integrated, patient-centered care continues to grow.
EUDA Expands Wellness Product Portfolio With A Next-Generation Immune Health Supplement
Published
Aug 26, 2025 8:00am EDT
SINGAPORE, Aug. 26, 2025 (GLOBE NEWSWIRE) — EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a leading Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that its wholly-owned subsidiary, EUDA Health Pte. Ltd., has secured exclusive worldwide distribution rights for a next-generation immune health supplement (the “Supplement”) from Chemokine Pte. Ltd. (“Chemokine”), a Singapore-based biotech company focused on molecular supplements and gene modulating formulations.
EUDA and its subsidiaries will market and sell the Supplement under the brand name, Euda Helixé, initially in Singapore, Malaysia, and China before expanding it to other markets in the future. The addition of the Supplement will further reinforce EUDA’s wellness product portfolio as it drives the transformation of the health and wellness landscape in the region.
The Supplement is an advanced formulation designed to modulate gene expression by activating beneficial genes while silencing harmful ones. Leveraging cutting-edge epigenetic technology, the Supplement enhances metabolism, boosts vitality, supports longevity, and is positioned as a foundational pillar in EUDA’s growing wellness product suite.
The Supplement builds on prior scientific advancements and proven formulation platforms to deliver molecular-level wellness support. The Supplement combines premium-grade ingredients including:
· Deer placenta· L-Glutathione· Astaxanthin· Marine collagen· Sea-Buckthorn oil· Grape seed oil· New Zealand refined avocado oil
Its capsule delivery system ensures active ingredients survive stomach acid and are released where absorption is maximized, enhancing efficacy.
Key Benefits of the Supplement
1. Gene-activated metabolic enhancement
2. Sustained energy and vigor via time-release delivery
3. Collagen-based youthfulness and skin regeneration
4. Longevity support through stem cell regeneration pathways
Chemokine was founded by Professor Kah Meng Lim, a molecular medicine researcher with deep scientific roots. Prof. Lim earned his Ph.D. in Molecular Medicine from the National University of Singapore and spent years in research roles under Singapore’s national R&D agency, A*STAR. His work bridges academic science and consumer health innovation, and he is widely respected for translating complex biological discoveries into practical health applications.
Mr. Alfred Lim, CEO of EUDA, commented, “Securing exclusive distribution rights for such a special product will reinforce our portfolio of wellness product offerings and further diversify our revenue streams. The Supplement positions EUDA at the forefront of molecular precision wellness, leveraging breakthrough gene activation technology. With our strong regional ecosystem and distribution capabilities, we believe that it is possible to generate sales of about 500,000 bottles over the next 12 months.”
EUDA Partners with Authorized Distributor of Guangdong Cell Biotech to Offer Stem Cell Therapies to Customers in Singapore and Malaysia
Published
Apr 24, 2025 7:00am EDT
SINGAPORE, April 24, 2025 (GLOBE NEWSWIRE) — EUDA Health Holdings Limited (“EUDA” or the “Company”) (NASDAQ: EUDA), a Singapore-based property management services provider and a leading non-invasive healthcare provider in Singapore and Malaysia, today announced an update to the potential strategic partnership, previously announced in December 2024, with Guangdong Cell Biotech Co. Ltd. (“Guangdong Cell Biotech”). Guangdong Cell Biotech is a prominent player in stem cell therapies and regenerative medicine in China. It develops autologous cell treatments and tailored medicines for various disorders.
Instead of the initially contemplated joint venture, the parties have adopted a commercial distribution arrangement structure that better aligns with their respective operational models and regional market dynamics.
On April 22, 2025, CK Health Plus Sdn Bhd (“CK Health”), a wholly-owned subsidiary of EUDA and a direct seller of holistic wellness consumer products, signed a collaboration agreement with Guangdong Key Lock Health Management Co., Ltd. (“Keylock”), an authorized distributor of Guangdong Cell Biotech. Pursuant to this collaboration agreement, CK Health will market and sell to EUDA customers in Singapore and Malaysia stem cell therapies provided by Guangdong Cell Biotech in China.
This revised structure builds upon the original strategic intent of the parties to collaborate, giving EUDA access to Guangdong Cell Biotech’s cutting-edge stem cell therapies and regenerative medicine.
“This commercial distribution structure showcases our strategy to diversify our business and revenue streams,” said Mr. Alfred Lim, CEO of EUDA. “Combining our mission to expand access to holistic healthcare solutions in Southeast Asia with Guangdong Cell Biotech’s established stem cell therapies, we aim to transform the health and wellness landscape in the region.”
NEWS
EUDA Expands Wellness Product Portfolio With A Next-Generation Immune Health Supplement
2 hours ago
Apr 24, 2025
Dec 16, 2024
May 8, 2024
EUDA Health Expands into Direct Selling Holistic Wellness Products with Acquisition of CK Health
May 6, 2024
MANAGEMENT
SINCERELY,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF THIRTEEN THOUSAND FIVE HUNDRED USD BY SHORE THING MEDIA LLC FOR A ONE DAY EUDA AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.